Serplulimab 是潜在有价值的治疗药物，但患者、医生和决策者对这种新药物的成本效益及其相应的合理价格存在不确定性。本研究旨在模拟 Serplulimab 作为第一线治疗美国（US）和中国广泛分期小细胞肺癌（ES-SCLC）患者的成本有效价格。在这项经济评估中，从美国和中国付款人的角度构建了分割生存模型。患者的基本特征和关键临床数据来自 ASTRUM-005。成本和效用来自公开获取的数据库和已发表的文献。测量和比较了累计成本（美元），生活年数，经过质量调整的生活年数（QALYs）和增量成本效益比率（ICERs）。进行价格模拟以通知根据给定的愿意支付（WTP）阈值制定价格策略。通过敏感性分析和场景分析评估了模型的鲁棒性；还包括亚组分析。基准分析表明，Serplulimab（$818.16/100 mg）在美国的WTP阈值为$150,000时具有成本效益性，有效性提高了0.61 QALYs，额外成本为$64,918（ICER $106,757）。 Serplulimab（$818.16/100 mg，考虑患者援助计划）在中国具有成本效益性，有效性提高了0.58 QALYs，总成本增加$19,369（ICER $33,392）。价格模拟结果表明，在WTP阈值为$100,000和$150,000时，当价格低于$762.11/100 mg和$1261.57/100 mg时，Serplulimab 在美国更受欢迎；当价格低于$373.37/100 mg时，在中国的WTP阈值为$38,184时具有成本效益性。敏感性分析显示以上结果是稳定的。亚组分析结果表明，尽管在某些亚组中 Serplulimab 不具备成本效益性，但总体趋势表明具有更好的生存优势的亚组更有可能具备成本效益性。Serplulimab 在美国和中国都可能是有价值且具有成本效益的治疗药物。本研究提供的基于证据的定价策略可帮助决策者做出最佳决策，以及医生进行一般的临床实践。需要更多关于预算影响和患者负担能力的证据。 © 2023年，作者（专属许可）Springer Nature Switzerland AG 发表。

Serplulimab is a potential valuable therapy, while patients, physicians, and decision-makers are uncertain about the cost-effectiveness of this novel drug and its corresponding reasonable price. This study aimed to simulate the price at which serplulimab was cost-effective as first-line therapy for United States (US) and Chinese extensive-stage small-cell lung cancer (ES-SCLC) patients.In this economic evaluation, a partitioned survival model was constructed from the perspective of US and Chinese payers. Baseline characteristics of patients and critical clinical data were obtained from ASTRUM-005. Costs and utilities were collected from open-access databases and published literature. Cumulative costs (in US dollars), life years, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were measured and compared. Price simulation was conducted to inform the pricing strategy at the given willingness-to-pay (WTP) threshold. The robustness of the model was assessed via sensitivity analyses and scenario analyses; subgroup analyses were also included.Base-case analysis indicated that serplulimab ($818.16/100 mg) would be cost-effective in the US at the WTP threshold of $150,000, with improved effectiveness of 0.61 QALYs and an additional cost of $64,918 (ICER $106,757). Serplulimab ($818.16/100 mg, patient assistance program considered) was cost-effective in China, with improved effectiveness of 0.58 QALYs and an increased overall cost of $19,369 (ICER $33,392). The price simulation results indicated that serplulimab was favored in the US when the price was less than $762.11/100 mg and $1261.57/100 mg at the WTP threshold of $100,000 and $150,000, respectively; it was cost-effective at the WTP threshold of $38,184 when the price was less than $373.37/100 mg in China. Sensitivity analyses revealed that the above results were stable. Subgroup analysis results indicated an overall trend for subgroups with better survival advantages to have a higher probability of cost-effectiveness, despite serplulimab not being cost-effective in some subgroups.Serplulimab might be a valuable and cost-effective therapy in both the US and China. The evidence-based pricing strategy provided by this study could benefit decision-makers in making optimal decisions and clinicians in general clinical practice. More evidence about the budget impact and affordability for patients is needed.© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.